<DOC>
	<DOCNO>NCT00348088</DOCNO>
	<brief_summary>The purpose study measure level specific protein , CXCL1 , blood patient untreated , metastatic ( Stage IV ) melanoma . These level compare blood level normal control . If level elevate metastatic melanoma , study determine correlate presence extent disease pursue .</brief_summary>
	<brief_title>Melanoma Biomarker Study</brief_title>
	<detailed_description>Malignant Melanoma rapidly increase incidence past thirty year , rate roughly 3 % per year . In 2005 , approximately 59,000 new case melanoma diagnosed 8000 death . While majority early melanomas surgically cure , advanced melanoma extremely poor prognosis . Current chemotherapy immunotherapy option advance melanoma still offer response rate 10-20 % . Thus , elucidation biomarkers melanoma , diagnostic prognostic , important area investigation . CXCL1 chemokine whose expression upregulated melanoma . We postulate CXCL1 play important role progression melanoma invasive disease . Our hypothesis state serum CXCL1 level correlate presence melanoma . Aims : 1 . To measure serum level CXCL1 untreated , metastatic melanoma patient compare serum CXCL1 level normal control . 2 . To measure compare centrally peripherally collect serum CXCL1 level untreated , metastatic melanoma . Blood collect metastatic melanoma patient one occasion , peripherally centrally . Control blood collect peripherally one occasion . The blood process test blind , batch fashion .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Histologic diagnosis melanoma ; primary may cutaneous , mucosal ocular . 2 . Evidence metastatic disease base standard AJCC staging . 3 . Willing give write informed consent . 4 . Willing able comply protocol procedure . 5 . At least 18 year age . 6 . No prior chemotherapy , immunotherapy , radiotherapy . 7 . Are able safely donate 50 mL blood . 8 . Have central venous catheter place ( place participation trial ) 1 . Known diagnosis chronic inflammatory disease , ie : Rheumatoid Arthritis , Systemic Sclerosis , Inflammatory bowel disease 2 . Known diagnosis NYHA class 3 4 Congestive Heart Failure 3 . Are unable safely donate 50 mL blood 4 . Known HIV , Hepatitis B , Hepatitis C infection . 5 . Any malignancy within 5 year , melanoma ( patient ) ; Have malignancy within past 5 year include melanoma ( normal control ) . Basal cell squamous cell skin cancer permit participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Untreated</keyword>
	<keyword>Biomarker</keyword>
</DOC>